Title Center Name Physician

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

NCT ID : 03237325
Protocol Number : IDR-OM-02
Phase : 3

Brain Tumors & Neuroscience

Dr. Mena

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

NCT ID : 4191135
Phase : 2 and 3

Breast Surgery and Oncology

Dr. O'Day

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)

NCT ID : 03697109
Phase : 3

Brain Tumors & Neuroscience

Dr. Barkhoudarian

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

NCT ID : 03822117
Phase : 2

Brain Tumors & Neuroscience

Dr. Kesari

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (AscenD-LB)

NCT ID : 04001517
Phase : 2

Brain Tumors & Neuroscience

Dr. Kesari

An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

NCT ID : 04136808

Urology and Urologic Oncology

Dr. Twardowski

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) (KEYLYNK-008)

NCT ID : 03976362
Protocol Number : MK-7339-008
Phase : 3

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Dr. Mena

A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (KEYLYNK-006)

NCT ID : 03976323
Protocol Number : MK-7339-006
Phase : 3

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Dr. Mena

Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy

NCT ID : 02033616
Phase : 2

Gynecologic Oncology

Dr. Friedman

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)

NCT ID : 02947347
Phase : 3

Hematology Oncology

Dr. Mena

A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer

NCT ID : 02589938
Phase : 3

Brain Tumors & Neuroscience

Dr. Mena

A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic (IV) Non-Small-Cell Lung Cancer (ATALANTE 1)

NCT ID : 02654587

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Dr. Mena

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

NCT ID : 02954991
Phase : 2

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Dr. Mena

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

NCT ID : 01872975

Breast Surgery and Oncology

Dr. Sanghani

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

NCT ID : 03345095
Phase : 3

Brain Tumors & Neuroscience

Dr. Kesari

Pemetrexed for the Treatment of Chordoma

NCT ID : 03955042
Phase : 1

Brain Tumors & Neuroscience

Dr. Kesari

Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

NCT ID : 03688204

Breast Surgery and Oncology

Dr. Gordon and Dr. Grumley

A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy

NCT ID : 03978611
Phase : 1/2a

Melanoma, Skin and Soft Tissue Tumors

Dr. O'Day

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)

NCT ID : 03924895
Phase : 3

Urology and Urologic Oncology

Dr. Twardowski

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

NCT ID : 03924856
Phase : 3

Urology and Urologic Oncology

Dr. Twardowski

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy

NCT ID : 03898180
Protocol Number : MK-7902-011
Phase : 3

Urology and Urologic Oncology

Dr. Twardowski

StimRouter™ for Pain Management in Post-stroke Shoulder Pain (PSSP)

NCT ID : 03093935
Protocol Number : STMR – PAIN 002 PSSP

Brain Tumors & Neuroscience

Dr. Langevin

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT ID : 03709888
Protocol Number : JWCI-17-0101

Brain Tumors & Neuroscience

Dr. Kesari

An Exploratory Study of Caregiver Burden Among Family Caregivers of Patients With Cancer

NCT ID : 03069105

Cancer Support

Dr. Saria

CancerLife: Patient-Driven Solution in Cancer Care

NCT ID : 03371147

Cancer Support

Dr. Saria

Allogeneic Human Mesenchymal Stem Cells for Alzheimer’s Disease

NCT ID : 02833792
Protocol Number : STEM105-M-AD
Phase : 2

Brain Tumors & Neuroscience

Dr. Kesari

Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial

NCT ID : 02873312
Protocol Number : CP-STMR-OAB-002

Brain Tumors & Neuroscience

Dr. Langevin

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

NCT ID : 02847559
Protocol Number : NU 16C02
Phase : 2

Brain Tumors & Neuroscience

Dr. Kesari

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

NCT ID : 03425292
Protocol Number : JWCI-17-0801

Brain Tumors & Neuroscience

Dr. Kesari

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (STELLAR)

NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : 3

Brain Tumors & Neuroscience

Dr. Kesari

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer

NCT ID : NCT03860272
Protocol Number : C-800-01
Phase : 1

All Solid Tumors

Breast Surgery and Oncology

Melanoma, Skin and Soft Tissue Tumors

Dr. O'Day

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2

Breast Surgery and Oncology

Melanoma, Skin and Soft Tissue Tumors

Dr. O'Day

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2

All Solid Tumors

Melanoma, Skin and Soft Tissue Tumors

Dr. O'Day

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I

Brain Tumors & Neuroscience

Dr. Kesari

A Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab

NCT ID : 03538314
Protocol Number : UV1-hTERT-MM-103
Phase : I

Melanoma, Skin and Soft Tissue Tumors

Dr. O'Day

Phase II Trial of AV-GBM-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) as Adjunctive Therapy Following Primary Surgery plus Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03400917
Protocol Number : CL-GBM-P01-US
Phase : II

Brain Tumors & Neuroscience

Dr. Kesari

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

NCT ID : 03480646
Protocol Number : 1205-201
Phase : Ib/II

Urology and Urologic Oncology

Dr. Twardowski

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3

Melanoma, Skin and Soft Tissue Tumors

Dr. O'Day

A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03463265
Protocol Number : GBM-007
Phase : 2

Brain Tumors & Neuroscience

Dr. Kesari

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2

All Solid Tumors

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Urology and Urologic Oncology

Dr. Twardowski

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT ID : 03425643
Protocol Number : MK-3475-671
Phase : IIB or IIIA

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Dr. O'Day

A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas

NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II

Brain Tumors & Neuroscience

Dr. Kesari

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy

NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II

Urology and Urologic Oncology

Dr. Twardowski

A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer

NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I

Brain Tumors & Neuroscience

Dr. Kesari

Recombinant Human Arginase 1 (RhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety And PK/PD

NCT ID : 02285101
Protocol Number : BCT-100-005
Phase : I

Melanoma, Skin and Soft Tissue Tumors

Dr. O'Day